Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
National Institute of Allergy and Infectious Diseases (NIAID)
Sinead Delany-Moretlwe; James P Hughes; Peter Bock; Samuel Gurrion Ouma; Portia Hunidzarira; Dishiki Kalonji; Noel Kayange; Joseph Makhema; Patricia Mandima; Carrie Mathew; Elizabeth Spooner; Juliet Mpendo; Pamela Mukwekwerere; Nyaradzo Mgodi; Patricia Nahirya Ntege; Gonasagrie Nair; Clemensia Nakabiito; Harriet Nuwagaba-Biribonwoha; Ravindre Panchia; Nishanta Singh; Bekezela Siziba; Jennifer Farrior; Scott Rose; Peter L Anderson; Susan H Eshleman; Mark A Marzinke; Craig W Hendrix; Stephanie Beigel-Orme; Sybil Hosek; Elizabeth Tolley; Nirupama Sista; Adeola Adeyeye; James F Rooney; Alex Rinehart; William R Spreen; Kimberly Smith; Brett Hanscom; Myron S Cohen; Mina C Hosseinipour; HPTN 084 study group
Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ; Statistical Centre for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.